摘要
目的探讨利拉鲁肽对初诊肥胖2型糖尿病的应用效果及对FGF-21、调节性T细胞及血清肝酶的影响。方法选择内分泌门诊确诊的81例初诊肥胖2型糖尿病患者作为研究对象,随机进行分组,对照组40例给予二甲双胍治疗,观察组41例加用利拉鲁肽治疗,治疗16周,比较治疗前后血糖、体重指数(BMI)变化情况,血浆FGF-21水平、外周血CD^(+)_(4)CD^(+)_(25)Foxp3+Treg细胞比例、血清肝酶指标。结果2组患者治疗后BMI,FPG,2 hPG,外周血FGF-21水平,血清肝酶ALT、AST、GGT水平均显著低于治疗前,CD^(+)_(4)CD^(+)_(25)Foxp3+Treg细胞比例较治疗前显著升高,差异有统计学意义(P<0.05);治疗后观察组BMI、FPG、2 hPG显著低于对照组,差异有统计学意义(P<0.05);治疗后观察组外周血FGF-21水平显著低于对照组,差异有统计学意义(P<0.05);治疗后观察组ALT、AST、GGT水平显著低于对照组,差异有统计学意义(P<0.05);治疗后观察组CD^(+)_(4)CD^(+)_(25)Foxp3+Treg细胞比例显著高于对照组,差异有统计学意义(P<0.05)。结论初诊肥胖2型糖尿病应用利拉鲁肽治疗具有良好的治疗效果,兼具控制血糖和BMI的作用,促进机体代谢的改善,其作用机制可能与降低FG F-21水平、提高调节T细胞比例以及降低血清肝酶水平有关。
Objective To investigate the therapeutic effects of liraglutide on newly diagnosed obesity type 2 diabetes mellitus and its effects on FGF-21,regulatory T cells and serum liver enzymes of patients.Methods A total of 81 patients with newly diagnosed obesity type 2 diabetes mellitus who were treated in our hospital from January 2017 to January 2019 were enrolled in the study,who were randomly divided into control group(n=40)and observation group(n=41).The patients in control group were treated by metformin,however,the patients in observation group,on the basis of control group,were treated by liraglutide,with a treatment course of 16 weeks for both groups.The changes of blood glucose,body mass index(BMI),blood plasma FG F-21 levels,peripheral blood CD^(+)_(4)CD^(+)_(25)Foxp3+TregCD 4+CD 25+Foxp3+Treg cells and serum liver enzyme indexes before and after treatment were observed and compared between the two groups.Results After treatment,the levels of BMI,FPG,2 hPG,FGF-21,and ALT,AST,GGT in both groups were significantly lower than those before treatment(P<0.05),however,the levels of CD 4+CD 25+Foxp3+Treg cells were significantly lower than those before treatment(P<0.05).After treatment the levels of BMI,FPG,2hPG,and FGF-21 as well as ALT,AST,GGT in observation group were significantly lower than those in control group(P<0.05),however,the levels of CD^(+)_(4)CD^(+)_(25)Foxp3+Treg in observation group were significantly higher than those in control group(P<0.05).Conclusion The therapeutic effects of liraglutide on newly diagnosed obesity type 2 diabetes are satisfactory,which can control blood glucose and improve BMI,and its action mechanism may be related to the decrease of FG f-21 and serum liver enzyme,and the increase of regulatory T cell proportion.
作者
王晶璞
卢燕
王会
WANG Jingpu;LU Yan;WANG Hui(Baoding Second Hospital,Hebei,Baoding 071000,China)
出处
《河北医药》
CAS
2021年第7期1066-1068,1072,共4页
Hebei Medical Journal
基金
保定市科学技术研究与发展计划项目(编号:1951ZF010)。
